Click here for more information about how we are dealing with COVID-19 and what you should do for your visit.
Skip to main content

Blog Archive

Neurology Diagnostics Digest - October 17, 2023 Oct 17th, 2023

Neurology Diagnostics’ Role in Advancing Alzheimer’s Research: LUCIDITY Phase 3 Outcomes We are excited to share our latest update on Alzheimer's research. The LUCIDITY Phase 3 trial, which was built upon the groundbreaking research conducted at Neurology Diagnostics in earlier phases, has shown a 93% reduction in a key biomarker...

Neurology Diagnostics’ Role in Advancing Alzheimer’s Research: LUCIDITY Phase 3 Outcomes Oct 16th, 2023

We are pleased to announce advancements in Alzheimer’s Disease research, stemming from the Phase 3 LUCIDITY trial. Neurology Diagnostics has had the privilege of participating in this trial, and are thrilled to share the compelling results, recently released. The LUCIDITY Phase 3 trial has brought to light exciting new evidence....

Neurology Diagnostics Digest - September 28, 2023 Sep 28th, 2023

New Referral Process We are excited to announce that we have a new referral upload form available for your convenience. You can now easily refer your patients to us by faxing over the attached form. We understand that many practices prefer to share referrals via fax or within your EMR...

FDA Approves Leqembi, Expanding Alzheimer's Treatment, with Contributions from Neurology Diagnostics Jul 12th, 2023

We are thrilled to share that the FDA has granted approval for Leqembi, a groundbreaking drug that offers new hope for Alzheimer's patients. Leqembi is an antibody that targets amyloid in the brain, in order to slow the progress of Alzheimer’s.  This approval is a significant achievement, particularly for our...

Neurology Diagnostics (NDx) Contributes to Lilly's Alzheimer's Clinical Trial Success May 8th, 2023

NDx is excited to announce our contribution to Lilly's ALZ 2 Trailblazer trial, which began in July 2020. We've been working with patients in this trial and have enrolled 39 patients, out of the total of over 1700 enrolled since the start of the trial!  We are proud to report...

New Test Offers Early Parkinson's Disease Detection: A Promising Step Forward in Parkinson's Awarene Apr 25th, 2023

April is Parkinson's Awareness Month, a time when people worldwide come together to raise awareness of Parkinson's disease and the impact it has on millions of people and their families. Parkinson's disease is a long-term illness that affects many people worldwide, causing problems with movement such as shaking, stiffness, and...

Dr. Joel Vandersluis, has been selected as a 2023 Health Care Hero. Mar 13th, 2023

We are thrilled to announce that our very own Dr. Joel Vandersluis has been selected as a 2023 Health Care Hero! This prestigious recognition celebrates those who have made significant contributions to health care through their concern for patients, their research and inventions, their management skills, their innovative programs for...

What Is Clinical Research? Sep 21st, 2021

What is clinical research? Clinical research is a medical research involving people. It is a branch of science that helps us gain knowledge about the disease progression, new medical drugs, procedures or devices. There are two types of clinical research: Clinical trial is an interventional study. It tests the safety...

Parkinson's Disease Clinical Trial Mar 8th, 2021

Parkinson's disease afflicts over one million people in the United States.  This disabling disease is the result of the destruction of neurons producing dopamine.  Dopamine is vital to our normal every day functions; from how you move your body, to how your mind controls your thoughts.  As the disease progresses...

Alzheimer's Phase 2 Clinical Trial Success Jan 20th, 2021

The Eli Lilly Alzheimer's Phase 2 clinical trial shows promising results and success in slowing the decline seen in dementia patients.  The New York Times reported on the success of the small clinical trial by Eli Lilly and Company January 11, 2021.  Neurology Diagnostics proudly announces that we are a top...